Camizestrant combined with CDK4/6 inhibitors shows antitumor activity and is well-tolerated in ER+, HER2– advanced breast ...
The global pacemakers market is on track to witness steady growth, projected at a rate of 3-4% annually by 2028. This expansion is fueled by a confluence of factors, from the growing burden of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback